Tacrolimus Dose Requirement in De Novo Adult Kidney Transplant Patients Treated With Adoport® Can Be Anticipated
Transplant International · 2024
DOI: 10.3389/ti.2024.13495 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Transplant International, 2024. Verfasst von Pierre Marquet und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Toxicology and Pharmacovigilance, Centre Hospitalier Universitaire de Limoges, Limoges, France. Hauptthemen laut MEDLINE: Tacrolimus, Kidney Transplantation, Immunosuppressive Agents, Kidney Failure, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sandoz.
Abstract (Originalsprache)
All the factors potentially influencing tacrolimus dose requirement and combinations thereof have never been thoroughly investigated, precluding accurate prediction of tacrolimus starting dose. This prospective, non-interventional, multicenter study in de novo adult kidney transplant recipients over the first year after transplantation aimed to investigate the factors influencing tacrolimus dose-standardized trough blood concentration (C 0 /D) over the first week post-transplant (D4-D7, primary objective), D8-M3 and M3-M12 (secondary objectives). Statistical analysis employed mixed linear models with repeated measures. Eighteen sites enrolled 440 patients and followed them up for 9.5 ± 4.1 months. Age at baseline ( p = 0.0144), end-stage renal disease ( p = 0.0092), CYP3A phenotype ( p < 0.0001), dyslipidemia at baseline ( p = 0.0031), hematocrit ( p = 0.0026), total bilirubin ( p = 0.0261) and plasma creatinine ( p = 0.0484) independently increased with log(C 0 /D) over D4-D7, explaining together 72.3% of the interindividual variability, and representing a robust model to estimate tacrolimus initial dose. Donor age and CYP3A phenotype were also influential over D8-M3 and M3-12, in addition to recipient age. Corticosteroids, diabetes at baseline, and ASAT yielded inconstant results between D8-M3 and M3-M12. We found no ethnicity effect when CYP3A phenotype was accounted for, and no food effect. Intra-individual variability over M3-M12 was moderate, and significantly lower in patients with chronic hepatic disorder ( p = 0.0196) or cancer ( p = 0.0132).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Toxicology and Pharmacovigilance, Centre Hospitalier Universitaire de Limoges, Limoges, France.
- Pharmacology and Transplantation, UMR1248 Inserm Université de Limoges, Limoges, France.
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Université Paris Cité, Paris, France.
- Medical Department, SANDOZ S.A.S, Levallois-Perret, France.
- Clinical Operations Department, RCTs, Lyon, France.
- Medical Writing Department, RCTs, Lyon, France.
Förderung
- Sandoz
Zitieren
APA
Marquet, P., Anglicheau, D., Humeau, A., Adrouche, S., Saada, L., Bisiaux, J., Guillemin, S., Lardy-Cléaud, A., & Rostaing, L. (2024). Tacrolimus Dose Requirement in De Novo Adult Kidney Transplant Patients Treated With Adoport® Can Be Anticipated. Transplant International. https://doi.org/10.3389/ti.2024.13495
Vancouver
Marquet P, Anglicheau D, Humeau A, Adrouche S, Saada L, Bisiaux J, et al. Tacrolimus Dose Requirement in De Novo Adult Kidney Transplant Patients Treated With Adoport® Can Be Anticipated. Transplant International. 2024. doi:10.3389/ti.2024.13495
BibTeX
@article{Marquet2024,
author = {Marquet, Pierre and Anglicheau, Dany and Humeau, Antoine and Adrouche, Sofian and Saada, Lakhdar and Bisiaux, Julie and Guillemin, Sara and Lardy-Cléaud, Audrey and Rostaing, Lionel},
title = {Tacrolimus Dose Requirement in De Novo Adult Kidney Transplant Patients Treated With Adoport® Can Be Anticipated},
journal = {Transplant International},
year = {2024},
doi = {10.3389/ti.2024.13495}
}
EUVIMED